Naltrexone blockade of nicotine effects in cigarette smokers

Brauer, Lisa H.; Behm, Frédérique M.; Westman, Eric; Patel, Prity; Rose, Jed E.

doi:10.1007/s002130050957

Cited by 59 publications

(47 citation statements)

References 24 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We propose that this procedure is more relevant to screen than more traditional procedures that assess the effects of medications when non-quitting smokers have unrestricted access to smoking Perkins et al, 1992;Dawe et al, 1995;Benowitz et al, 1998;Brauer et al, 1999;Caskey et al, 1999;Jarvik et al, 2000;King and Meyer, 2000;Cousins et al, 2001;Houtsmuller et al, 2002). The main advantage to the present paradigm is that non-quitting smokers are forced to make an ''either/or'' choice between the cigarette and money, a situation that models the choice made by treatment-seekers who are motivated by intrinsic factors to quit smoking.…”

Section: Discussionmentioning

confidence: 99%

“…Studying effect of cigarettes in treatment seekers is constrained on the ethical grounds; therefore, many prior studies have modeled tobacco addiction by permitting unrestricted access to smoking in nonquitting smokers Perkins et al, 1992;Dawe et al, 1995;Benowitz et al, 1998;Brauer et al, 1999;Caskey et al, 1999Caskey et al, , 2002Jarvik et al, 2000;Cousins et al, 2001;Houtsmuller et al, 2002). However, this design may lack the sensitivity to detect weaker medication effects.…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Effects of alternative reinforcer and craving on the choice to smoke cigarettes in the laboratory

Bisaga

Padilla

Garawi

et al. 2006

Human Psychopharmacology

View full text Add to dashboard Cite

We examined to what extent craving for cigarettes and the magnitude of an alternative monetary reinforcer were predictors of the choice to smoke in the human laboratory. Twelve non-treatment-seeking nicotine-dependent volunteers participated in a series of outpatient sessions during which they had repeated opportunities to select between three puffs of a cigarette and a variety of monetary alternatives ($0.50-3), responding under a progressive-ratio schedule. Level of cigarette craving was measured at baseline and between each choice opportunity. The probability of choosing a cigarette decreased significantly with the increase in the magnitude of the alternative reinforcer. Baseline level of craving did not significantly alter the probability of choosing a cigarette, but a craving component related to the anticipation of positive effects from smoking, assessed repeatedly between choice opportunities, was predictive of the choice to smoke. These results demonstrate that the cigarette puff self-administration procedure is sensitive to environmental manipulations and cigarette puff choice can be modified by the availability of an alternative reinforcer. This paradigm models the motivational component associated with choice to smoke and could be used to evaluate the effects of pharmacological and behavioral interventions to decrease cigarette smoking.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

Effects of alternative reinforcer and craving on the choice to smoke cigarettes in the laboratory

Bisaga

Padilla

Garawi

et al. 2006

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Chronic nicotine has been shown to increase m-OR in striatum in female rats and in the ventral tegmental area in male and female mice (Walters et al, 2005;Wewers et al, 1999). The opiate antagonist naloxone can block the subjective effects of nicotine in chronic smokers (Brauer et al, 1999;King and Meyer, 2000). Thus, it is not surprising that naltrexone has been proposed for the treatment of nicotine dependence (Schnoll and Lerman, 2006).…”

Section: Discussionmentioning

confidence: 99%

Differences in δ- and μ-Opioid Receptor Blockade Measured by Positron Emission Tomography in Naltrexone-Treated Recently Abstinent Alcohol-Dependent Subjects

Weerts

Kim

Wand

et al. 2007

Neuropsychopharmacol

138

147

View full text Add to dashboard Cite

Blockade of brain m-opioid receptor (m-OR) and d-opioid receptor (d-OR) was investigated in recently abstinent alcohol-dependent subjects (N ¼ 21) maintained on naltrexone. Subjects completed a 19-day inpatient protocol, which included alcohol abstinence followed by naltrexone treatment (50 mg) on days 15-19. Blood samples were collected after the first administration of naltrexone to evaluate serum levels of naltrexone and 6-b-naltrexol. Regional brain m-OR binding potential (BP) and d-OR K i was measured using [ 11 C]carfentanil (CAR) positron emission tomography (PET) and [11 C]methyl naltrindole ([ 11 C]MeNTI) PET, respectively, before (day 5) and during naltrexone treatment (day 18). Naltrexone inhibition of [ 11 C]CAR BP was near maximal across all brain regions of interest with little variability across subjects (mean + SD% inhibition ¼ 94.9 + 4.9%). Naltrexone only partially inhibited the [ 11 C]MeNTI K i and there was more variability across subjects (mean + SD% inhibition ¼ 21.1 + 14.49%). Peak serum levels of naltrexone were positively correlated with % inhibition of d-OR K i in neocortex and basal ganglia. Peak serum levels of naltrexone were not correlated with % inhibition of m-OR BP. Peak levels of 6-b-naltrexol were not significantly correlated with % inhibition of m-OR BP or d-OR K i . Thus, the FDA recommended therapeutic dose of naltrexone was sufficient to produce near complete inhibition of the m-OR in recently abstinent alcohol dependent subjects. The lower percent inhibition of d-OR and greater variability in d-OR blockade by naltrexone across subjects may contribute to individual differences in treatment outcomes to naltrexone. Further investigations on the relationship between individual differences in d-OR blockade by naltrexone and clinical outcomes should be explored.

show abstract

“…In another recent acute dose study, naltrexone significantly reduced the total number of cigarettes smoked and expired carbon monoxide levels compared to placebo (Epstein and King 2004). Naltrexone administered orally for 1 week increased the aversive effects of the first cigarette smoked each day and attenuated the increased wakefulness after smoking without altering ad lib smoking in the laboratory setting (Brauer et al 1999). Taken together, these studies suggest that naltrexone may influence some aspects of cigarette smoking and not others.…”

Section: Introductionmentioning

confidence: 92%

Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm

et al. 2005

View full text Add to dashboard Cite

show abstract

Naltrexone blockade of nicotine effects in cigarette smokers

Abstract: The blockade of nicotine's effects by naltrexone supports a role for opioid mechanisms in cigarette smoking.

Cited by 59 publications

References 24 publications

Effects of alternative reinforcer and craving on the choice to smoke cigarettes in the laboratory

Effects of alternative reinforcer and craving on the choice to smoke cigarettes in the laboratory

Differences in δ- and μ-Opioid Receptor Blockade Measured by Positron Emission Tomography in Naltrexone-Treated Recently Abstinent Alcohol-Dependent Subjects

Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm

Contact Info

Product

Resources

About